WallStreetZenWallStreetZen

NASDAQ: TYRA
Tyra Biosciences Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for TYRA

Based on 7 analysts offering 12 month price targets for Tyra Biosciences Inc

Min Forecast
$30.00-3.23%
Avg Forecast
$42.29+36.41%
Max Forecast
$59.00+90.32%

Should I buy or sell TYRA stock?

Based on 7 analysts offering ratings for Tyra Biosciences Inc.

Strong Buy
Strong Buy
4 analysts 57.14%
Buy
3 analysts 42.86%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although TYRA's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates TYRA as a "Sell". Stocks with a Zen Rating of Sell have had an average return of -4.50% per year. Learn More

Be the first to know when Wall Street analysts revise their TYRA stock forecasts and price targets.

TYRA stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-02-03
lockedlocked$00.00+00.00%2026-02-03
lockedlocked$00.00+00.00%2026-01-28
lockedlocked$00.00+00.00%2026-01-23Find Out Why
lockedlocked$00.00+00.00%2025-12-16
Raymond James
Top 29%
72
Strong BuyInitiates Coverage On$35.00+12.90%2025-09-03
HC Wainwright & Co.
Top 18%
83
BuyReiterates$30.00-3.23%2025-08-22

1 of 1

Forecast return on equity

Is TYRA forecast to generate an efficient return?

Company
-7.76%
Industry
335.63%
Market
216.58%
TYRA's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is TYRA forecast to generate an efficient return on assets?

Company
-7.21%
Industry
119.72%
TYRA is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

TYRA earnings per share forecast

What is TYRA's earnings per share in the next 3 years based on estimates from 12 analysts?

Avg 1 year Forecast
-$2.31
Avg 2 year Forecast
-$2.37
Avg 3 year Forecast
-$1.12

TYRA revenue forecast

What is TYRA's revenue in the next 3 years based on estimates from 10 analysts?

Avg 1 year Forecast
$0.0
Avg 2 year Forecast
$0.0
Avg 3 year Forecast
$48.7M

TYRA vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
TYRA$31.00$42.29+36.41%Strong Buy
DFTX$16.90$36.00+113.02%Strong Buy
INVA$21.80$32.25+47.94%Buy
TNGX$12.51$14.60+16.71%Strong Buy
MBX$37.67$56.00+48.66%Strong Buy
View Top Biotech Stocks

Tyra Biosciences Stock Forecast FAQ

Is Tyra Biosciences Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 7 Wall Street analysts covering (NASDAQ: TYRA) stock is to Strong Buy TYRA stock.

Out of 7 analysts, 4 (57.14%) are recommending TYRA as a Strong Buy, 3 (42.86%) are recommending TYRA as a Buy, 0 (0%) are recommending TYRA as a Hold, 0 (0%) are recommending TYRA as a Sell, and 0 (0%) are recommending TYRA as a Strong Sell.

If you're new to stock investing, here's how to buy Tyra Biosciences stock.

What is TYRA's earnings growth forecast for 2026-2028?

(NASDAQ: TYRA) Tyra Biosciences's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 69.38%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 40.03%.

Tyra Biosciences's earnings in 2026 is -$111,684,000.On average, 12 Wall Street analysts forecast TYRA's earnings for 2026 to be -$123,422,977, with the lowest TYRA earnings forecast at -$140,699,525, and the highest TYRA earnings forecast at -$91,346,346. On average, 8 Wall Street analysts forecast TYRA's earnings for 2027 to be -$126,625,303, with the lowest TYRA earnings forecast at -$138,607,339, and the highest TYRA earnings forecast at -$103,114,893.

In 2028, TYRA is forecast to generate -$59,883,494 in earnings, with the lowest earnings forecast at -$57,535,122 and the highest earnings forecast at -$61,644,773.

What is TYRA's revenue growth forecast for 2026-2028?

(NASDAQ: TYRA) Tyra Biosciences's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 115.73%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 23.06%.

Tyra Biosciences's revenue in 2026 is $0.On average, 10 Wall Street analysts forecast TYRA's revenue for 2026 to be $0, with the lowest TYRA revenue forecast at $0, and the highest TYRA revenue forecast at $0. On average, 8 Wall Street analysts forecast TYRA's revenue for 2027 to be $0, with the lowest TYRA revenue forecast at $0, and the highest TYRA revenue forecast at $0.

In 2028, TYRA is forecast to generate $2,598,740,824 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $4,221,999,812.

What is TYRA's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: TYRA) forecast ROA is -7.21%, which is lower than the forecast US Biotechnology industry average of 119.72%.

What is TYRA's Price Target?

According to 7 Wall Street analysts that have issued a 1 year TYRA price target, the average TYRA price target is $42.29, with the highest TYRA stock price forecast at $59.00 and the lowest TYRA stock price forecast at $30.00.

On average, Wall Street analysts predict that Tyra Biosciences's share price could reach $42.29 by Feb 3, 2027. The average Tyra Biosciences stock price prediction forecasts a potential upside of 36.41% from the current TYRA share price of $31.00.

What is TYRA's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: TYRA) Tyra Biosciences's current Earnings Per Share (EPS) is -$1.87. On average, analysts forecast that TYRA's EPS will be -$2.31 for 2026, with the lowest EPS forecast at -$2.64, and the highest EPS forecast at -$1.71. On average, analysts forecast that TYRA's EPS will be -$2.37 for 2027, with the lowest EPS forecast at -$2.60, and the highest EPS forecast at -$1.93. In 2028, TYRA's EPS is forecast to hit -$1.12 (min: -$1.08, max: -$1.16).

What is TYRA's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: TYRA) forecast ROE is -7.76%, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.